^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Intron A (interferon α-2b)

    i
    Other names: SCH 30500, YM 14090
    Company:
    Biogen, Merck (MSD)
    Drug class:
    IFNα 2b stimulant
    Related drugs:
    3ms
    NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=30 --> 12 | Trial primary completion date: Nov 2026 --> Jun 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aspirin
    5ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=1, Terminated, Roswell Park Cancer Institute | Trial completion date: Apr 2026 --> Jun 2025 | Active, not recruiting --> Terminated; Funding completed
    Trial completion date • Trial termination
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    7ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=1, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=24 --> 1 | Trial completion date: Nov 2027 --> Apr 2026 | Trial primary completion date: Nov 2027 --> Apr 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    8ms
    NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov)
    P2, N=30, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aspirin
    8ms
    E1609: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (clinicaltrials.gov)
    P3, N=1673, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Yervoy (ipilimumab) • Intron A (interferon α-2b)
    9ms
    SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov)
    P3, N=1301, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • Intron A (interferon α-2b)
    9ms
    Hypoxia-induced ATF3 escalates breast cancer invasion by increasing collagen deposition via P4HA1. (PubMed, Cell Death Dis)
    These results reveal a novel hypoxia-induced HIF1ɑ-ATF3-P4HA1 axis which can potentially be exploited as a therapeutic target to impede EMT and ultimately breast cancer invasion. Hypoxia induced ATF3 regulates P4HA1 expression and alternative splicing to promote breast cancer invasion.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • ATF3 (Activating Transcription Factor 3) • P4HA1 (Prolyl 4-Hydroxylase Subunit Alpha 1)
    |
    Intron A (interferon α-2b)
    9ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    1year
    MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (clinicaltrials.gov)
    P3, N=586, Recruiting, University of Birmingham | Trial completion date: Feb 2028 --> Apr 2030 | Trial primary completion date: Aug 2026 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • hydroxyurea • Intron A (interferon α-2b)
    1year
    A exploratory study to evaluate the efficacy and safety of interferon-α combined with ATO in the treatment of arsenic-resistant acute promyelocytic leukemia (ChiCTR2400089805)
    P=N/A, N=15, Not yet recruiting, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital
    New trial
    |
    PML (Promyelocytic Leukemia)
    |
    Venclexta (venetoclax) • Intron A (interferon α-2b)
    1year
    Commitment Complex Splicing Factors in Cancers of the Gastrointestinal Tract-An In Silico Study. (PubMed, Bioinform Biol Insights)
    This study demonstrates the versatility of in silico analysis to determine molecular function of large macromolecular complexes such as the spliceosome CC. Furthermore, our analysis indicates that therapeutic lowering of CC levels in colon cancer patients may enhance patient survival.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • U2AF1 mutation
    |
    Intron A (interferon α-2b)
    over1year
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral